PF-Atlas › Clinical Trials › ENTR-01-IPF

ENTR-01 WNT Pathway Agonist Phase I

ENTR-01 · WNT/AEC2 Expansion · Phase 1

Registry ID
ENTR-01-IPF
Phase
Phase 1
Status
Recruiting
Drug / intervention
ENTR-01
Mechanism
WNT/AEC2 Expansion
Sponsor
Entrega Bio
Start
2025-01

About this trial

ENTR-01 is evaluated in ENTR-01-IPF, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Entrega Bio, targeting wnt/aec2 expansion. Current status: Recruiting.

View ENTR-01-IPF on ClinicalTrials.gov →

Explore related

WNT/RSPO3 Agonist — Treatment profileAll ENTR-01 trialsWNT/AEC2 Expansion mechanismAll IPF trials
Medical disclaimer. This page summarizes public trial data for ENTR-01-IPF for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.